169 Results (Page 2 of 7)
Mexico Markets Research Reports
Mexico Cardiovascular Diseases Therapeutics Market Analysis
The Mexico cardiovascular disease therapeutics market is expected to witness growth from $2.44 Bn in 2022 to $4.34 Bn in 2030 with a CAGR of 7.47% for the year 2022-2030. The improvement in health infrastructure and spending and the development of new therapeutics in Mexico are responsible for the expansion of the market. The Mexico cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Liomont, Vitalmex, and Sanofi are the major players in the Mexico cardiovascular disease therapeutics market.
Mexico Over The Counter (OTC) Analgesics Market Analysis
This report presents a strategic analysis of the Mexico Over The Counter (OTC) Analgesics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Mexico Over The Counter (OTC) Analgesics Market, offering unmatched value, accuracy and expert insights.
Mexico Chronic Cough Therapeutics Market Analysis
Mexico Chronic Cough Therapeutics Market was valued at $95 Mn in 2022 and is estimated to reach $179 Mn in 2030, exhibiting a CAGR of 8.35% during the forecast period. The main driver behind the growth of the chronic cough therapeutics market is the extensive prevalence of chronic respiratory infections, often signaled by the occurrence of chronic cough. Presently, key participants in this market consist of Cipla Inc., Reckitt Benckiser Group plc., Hikma Pharmaceuticals Plc, Merck, Novartis, Bellus Health, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb, and Bayer.
Mexico Connected Healthcare Market Analysis
Mexico connected healthcare market is projected to grow from $995.4 Mn in 2022 to $7469.23 Mn by 2030, registering a CAGR of 28.65% during the forecast period of 2022-30. The main factors driving the growth would be increasing technological adoption, the ageing population, the rising prevalence of chronic diseases and government support. The market is segmented by type, function and by application. Some of the major players include Okani, Prosperia, Cuentame, Medtronic, Honeywell, Siemens Healthineer and GE Healthcare.
Mexico Medical and Diagnostic Laboratory Service Market Analysis
This report presents a strategic analysis of the Mexico Medical and Diagnostic Laboratory Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Mexico Medical and Diagnostic Laboratory Service Market, offering unmatched value, accuracy and expert insights.
Mexico Patient Support Programs (PSP) Market Analysis
This report presents a strategic analysis of the Mexico Patient Support Programs (PSP) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Mexico Patient Support Programs (PSP) Market, offering unmatched value, accuracy and expert insights.
Mexico Clinical Diagnostics Market Analysis
This report presents a strategic analysis of the Mexico Clinical Diagnostics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Mexico Clinical Diagnostics Market, offering unmatched value, accuracy and expert insights.
Mexico Breast Cancer Therapeutics Market Analysis
As new targeted therapies are being developed in Mexico, there is significant growth being observed in the Mexico breast cancer therapeutics market from $273 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-30. The market is segmented by therapy, by cancer type, and by distribution channel. Lupin, Sanofi, and Teva Pharmaceuticals are some of the major competitors in the Mexico breast cancer therapeutics market.
Mexico Diabetes Drugs Market Analysis
This report presents a strategic analysis of the Mexico Diabetes Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Mexico Diabetes Drugs Market, offering unmatched value, accuracy and expert insights.
Mexico Healthcare Diagnostics Market Analysis
This report presents a strategic analysis of the Mexico Healthcare Diagnostics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Mexico Healthcare Diagnostics Market, offering unmatched value, accuracy and expert insights.
Mexico Nutritional Supplements Market Analysis
Mexico's nutritional supplements market is projected to grow from $9.2 Mn in 2022 to $14.96 Mn by 2030, registering a CAGR of 7.4% during the forecast period of 2022-2030. The market for nutritional supplements in Mexico is a growing industry, with an increasing number of consumers seeking out products to support their health and wellness. The market is expected to continue to grow in the coming years, driven by factors such as an ageing population, increasing disposable incomes, and growing awareness of the importance of good nutrition. The key players in the Mexican nutritional supplements market include companies such as Herbalife, GNC, and Amway. Additionally, many local players such as FEMSA, Bimbo and Soriana also have a strong presence in the market.
Mexico Cholesterol Therapeutics Market Analysis
The Mexico Cholesterol Therapeutics Market is anticipated to experience a growth from $365 Mn in 2022 to $456 Mn by 2030, with a CAGR of 2.85% during the forecast period of 2022-2030. The key drivers of this market include the rising incidence of cardiovascular diseases, heightened awareness and screening programs, advancements in drug development, and the associated demand for more affordable and effective cholesterol-lowering medications. The Mexico Cholesterol Therapeutics Market encompasses various players across different segments, Amgen, Pfizer, Merck, AstraZeneca, Johnson & Johnson, Sanofi, AbbVie, PISA, Sanfer, Senosiain, etc, among various others.
Mexico Cardiac Arrhythmia Therapeutics Market Analysis
Mexico Cardiac Arrhythmia Therapeutics Market valued at $108 Mn in 2022, projected to reach $173 Mn by 2030 with a 6.05% CAGR. The key drivers of this industry include the increasing prevalence of cardiac conditions, technological advancements, and expanding healthcare infrastructure. The industry is primarily dominated by players such as Abbott, Medtronic, Biotronik, Philips, GE, Johnson & Johnson, and Boston Scientific among others.
Mexico Alzheimer’s Therapeutics Market Analysis
Mexico alzheimer’s therapeutics market valued at $72 Mn in 2022, projected to reach $147 Mn by 2030 with a 9.35% CAGR. One of the main factors propelling the market's growth is the rising demand for Alzheimer's treatment pharmaceuticals as a result of the increasing prevalence of Alzheimer's disease among the aging population. Top leading pharmaceutical companies presently operating in the market are Pfizer, Janssen, Eisai, Biogen, Novartis, Roche, Lundbeck, Otsuka Pharmaceutical, Teva Pharmaceutical and Sun Pharmaceutical.
Mexico Infectious Disease Drugs Market Analysis
Mexico Infectious Disease Drugs Market valued at $1.78 Bn in 2023, projected to reach $2.43 Bn by 2030 with a 4.52% CAGR. The market is being driven by advancements in healthcare infrastructure, government initiatives, and rising awareness about infectious diseases. The market is dominated by key players like AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, Sanofi S.A., Bayer AG, and Astellas Pharma Inc.
Mexico Atopic Dermatitis Therapeutics Market Analysis
The Mexico Atopic Dermatitis Therapeutics Market was valued at US $185 Mn in 2022, and is predicted to grow at (CAGR) of 9.05% from 2023 to 2030, to US $369 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, Merck among others.
Mexico Atherosclerosis Therapeutics Market Analysis
Mexico Atherosclerosis Therapeutics Market was valued at $42 Mn in 2022 and is estimated to reach $67 Mn in 2030, exhibiting a CAGR of 5.95% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the growing incidence of cardiovascular diseases, which are being exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The market is currently dominated by leading pharmaceutical companies, including Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Johnson & Johnson, Teva Pharmaceutical, Roche, and Merck & Co.
Mexico Asthma and COPD Therapeutics Market Analysis
The Mexico Asthma and COPD Therapeutics Market was valued at US $501 Mn in 2022, and is predicted to grow at (CAGR) of 5.45% from 2023 to 2030, to US $766 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and asthma, increasing demand, supportive policies, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Tetherex, Novartis, AstraZeneca, Verona, and Boehringer Ingelheim, among others
Mexico HIV Drugs Market Analysis
Mexico HIV Drugs Market is at around $0.48 Bn in 2023 and is projected to reach $0.62 Bn in 2030, exhibiting a CAGR of 3.85% during the forecast period. Increasing HIV prevalence, government initiatives, and the expansion of healthcare infrastructure are propelling the market growth. The market is dominated by key players like Genomma Lab Internacional, Laboratories Chinoin, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.
Mexico Antifungal Drugs Market Analysis
Mexico Antifungal Drugs Market is at around $0.2 Bn in 2023 and is projected to reach $0.3 Bn in 2030, exhibiting a CAGR of 4.05% during the forecast period. The market is being driven by innovations and developments in drugs, awareness, and education about fungal infections, and healthcare infrastructure. The market is dominated by key players like Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Mexico Anemia Therapeutics Market Analysis
The Mexico Anemia Therapeutics Market is anticipated to experience a growth from $222 Mn in 2022 to $454 Mn by 2030, with a CAGR of 9.35% during the forecast period of 2022-2030. The market drivers for the Mexico Anemia Therapeutics Market include factors like increased awareness and early intervention driven by the risks of untreated anemia, the exploration of newer and more effective treatment options by pharmaceutical firms globally, and the impact of socio-economic factors contributing to a higher prevalence of anemia. The Mexico Anemia Therapeutics Market encompasses various players across different segments, including Abbott, Amgen, Johnson & Johnson, Roche, Pfizer, Biosan, Solfarma, Liomont Laboratories, Pisa Laboratories, Genomma Lab International etc, among various others.
Mexico Antibacterial (Antibiotics) Drugs Market Analysis
Mexico Antibacterial (Antibiotics) Drugs Market is at around $0.76 Bn in 2023 and is projected to reach $1.04 Bn in 2030, exhibiting a CAGR of 4.45% during the forecast period. The industry is expanding due to factors like medical tourism, increased resistance to antibiotics, and awareness and education. The market is dominated by key players like AbbVie (Allergan), Pfizer, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Sanofi S.A., Novartis AG, Eli Lilly, and Bayer.
Mexico Dermatological Therapeutics Market Analysis
Mexico Dermatological Therapeutics Market is at around $0.62 Bn in 2022 and is projected to reach $1.11 Bn in 2030, exhibiting a CAGR of 8.85% during the forecast period. The market is rapidly expanding as a result of the increased prevalence of dermatological conditions, rising awareness about skin disorders, and technological advancements in the industry. The market is dominated by key players like Genomma Lab Internacional, Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma Laboratories, Bausch Health Companies Inc., Novartis AG, Eli Lily and Company, and GlaxoSmithKline PLC.
Mexico Alopecia (Hair Loss) Therapeutics Market Analysis
The Mexico Alopecia (Hair Loss) Therapeutics Market was valued at US $123 Mn in 2022, and is predicted to grow at (CAGR) of 7.75% from 2023 to 2030, to US $223 Mn by 2030. The key drivers of this industry include the surge in the prevalence of Alopecia (hair loss), increased disposable income, lifestyle changes and others. The industry is primarily dominated by players such as Johnson & Johnson, Eli Lilly, Merck, Pfizer, Cipla, Sun Pharmaceuticals, and iRestore, among others
Mexico Digital Therapeutics Market Analysis
Mexico Digital Therapeutics Market is at around $93 Mn in 2023 and is projected to reach $508 Mn in 2030, exhibiting a CAGR of 27.45% during the forecast period. The market is propelling due to factors such as the rising prevalence of chronic diseases, the expansion of telehealth, and the rise in patient engagement and awareness. The market is dominated by key players like Omada Health Inc., 2Morrow Inc., Livongo Health Inc., WellDoc, Propeller Health, Canary Health, Noom Inc., Akili Interactive Labs Inc., and HYGIEIA.